BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Lunit to Supply AI Platform to Australia's BreastScreen NSW Machine Reading Project

Lunit's INSIGHT MMG solution has been selected for mammogram screening in Australia's BreastScreen NSW's AI evaluation and clinical integration...

November 17, 2022 | News

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Summary of Study Outcomes ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met ...

November 07, 2022 | News

Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

November 07, 2022 | News

Australia First in-human use of OncoRes Medical's cancer imaging system successful

OncoRes Medical today announces positive data from the first in-cavity use of its Quantitative Micro-Elastography (QME) Imaging System. The study, titled&n...

November 03, 2022 | News

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

If adopted, the rule would eliminate all cost to Medicare patients for a follow-up colonoscopy after a positive at-home colorectal cancer screening test. A...

November 02, 2022 | News

Irish oncology care platform announces collaboration with NCCN

The Irish-founded oncology software company, ONCOassist, today announces a new agreement with The National Comprehensive Cancer Network® (NCCN®). T...

October 18, 2022 | News

Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

The IND application was submitted in partnership with Grand Pharmaceutical Group Limited (Grand Pharma), Telix's partner in the Greater China reg...

October 17, 2022 | News

Health Canada Approves Illuccix® for Prostate Cancer Imaging

Illuccix™ [kit for the preparation of gallium (68Ga) gozetotide injection], after radiolabeling with gallium (68Ga), is indicated for use with the po...

October 14, 2022 | News

First patient treated in Clarity's therapeutic prostate cancer trial

Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT0...

October 10, 2022 | News

China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...

October 10, 2022 | News

First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent

As Illuccix rolls out to positron emission tomography (PET) sites across the country, Mercy Radiology in Auckland became the first to administer ...

September 30, 2022 | News

Australia approved New treatment for rare cancer cholangiocarcinoma

A NEW targeted therapy to treat a rare bile duct cancer called cholangiocarcinoma has been approved for use in Australia. PEMAZYRE® (pemigat...

September 16, 2022 | News

Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients

First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...

September 14, 2022 | News

SeekIn Receives CE Mark Approval for OncoSeek® Multi-Cancer Detection Test

SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approva...

September 13, 2022 | News

Stay Connected